ArticleNeurology(R) neuroimmunology & neuroinflammation2016
Infliximab is a plausible alternative for neurologic complications of Behçet disease.
Article in Neurology(R) neuroimmunology & neuroinflammation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 3 syntheses or guidelines pooled it, 71 citations in OpenAlex.
- The effectiveness of the anti-tumor necrosis factor therapy infliximab in neuro-Behçet's disease: a systematic review and meta-analysis.The Journal of international medical research · 2023Pooled it
- Recommendations for the Management of Neuro-Behçet's Disease by the Japanese National Research Committee for Behçet's Disease.Internal medicine (Tokyo, Japan) · 2020Pooled it
- The right place of interleukin-1 inhibitors in the treatment of Behçet's syndrome: a systematic review.Rheumatology international · 2019Pooled it
- Management of major organ involvement in Behçet syndrome: a systematic literature review informing the 2025 update of the EULAR recommendations.EULAR rheumatology open · 2026Article
- Article
- Neuro-behcet's syndrome: epidemiology, mechanisms, and emerging strategies in diagnosis and treatment.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Review
- Exploring medication adherence in Behçet's disease following COVID-19: a mixed-methods study.Orphanet journal of rare diseases · 2025Article
- Can infliximab serve as a new therapy for neuropsychiatric symptoms?Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Long-term outcomes of infliximab treatment in neuro-Behcet syndrome: A single-center retrospective study.Clinical rheumatology · 2024Observational
- Neurological and Vascular Behçet's Disease in a Young Male without Classic Triad of Behçet's Disease: A Case Report and Literature Review.Mediterranean journal of rheumatology · 2024Article
- Treatment Options in Pediatric Behçet's Disease.Paediatric drugs · 2023Review
- The impact of Behçet's disease on intimate relationships in women: A qualitative study.Chronic illness · 2022Article
- Biologic treatments in Behçet's disease.European journal of rheumatology · 2021Article
- Behçet syndrome.Nature reviews. Disease primers · 2021Review
- Behçet Disease: An Update for Dermatologists.American journal of clinical dermatology · 2021Review
- Advances in the Treatment of Behcet's Disease.Current rheumatology reports · 2021Review
- Experimental Therapeutic Solutions for Behcet's Disease.Journal of experimental pharmacology · 2021Review
- Recent Insights into the Management of Behçet Syndrome.Journal of inflammation research · 2021Review
- Treatment of Behçet's Disease: An Algorithmic Multidisciplinary Approach.Frontiers in medicine · 2021Review
- Optic neuritis as a presenting feature of Behçet's disease: case-based review.Rheumatology international · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveWe evaluated the effectiveness of infliximab in patients with neuro-Behçet syndrome for whom other immunosuppressive medications had failed.
methodsPatients whose common immunosuppressive medications fail in recurrent neuro-Behçet syndrome need an alternative. We report our experience with the tumor necrosis factor α blocker infliximab for long-term treatment of neuro-Behçet syndrome. We recruited patients within a multidisciplinary referral practice of Behçet disease and prospectively followed everyone with a neurologic symptom(s). Patients (n = 16) with ≥2 neurologic bouts (excluding purely progressive disease) while on another immunosuppressive treatment were switched to and successfully sustained on infliximab (5 mg/kg in weeks 0, 2, and 6, then once every 8 weeks; minimum follow-up duration ≥12 months). Infliximab was stopped within 2 months after initiation in one patient because of pulmonary and CNS tuberculosis.
resultsPatients had stepwise worsening due to relapses in the Expanded Disability Status Scale modified for neuro-Behçet syndrome before switching to infliximab (median score of 5.0, range 2.0-7.0; median neuro-Behçet syndrome duration 29.1 months, range 5.0-180.7). Median duration of preinfliximab immunosuppressive medication use was 20.0 months (range 3.0-180.7). In all 15 patients, during infliximab treatment (median score 4.0, range 2.0-7.0; median duration 39.0 months, range 16.0-104.9 months), neurologic relapses were completely aborted and there was no further disability accumulation.
conclusionWe observed a significant beneficial effect of infliximab in neuro-Behçet syndrome. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that for patients with neuro-Behçet syndrome whose other immunosuppressive medications failed, infliximab prevents further relapses and stabilizes disability.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.